RxDoctor Payments Data

Lisa York

Family · Milwaukee, WINPI 1316517824

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $3,216 of the $5,150 with a category attached, or 62.5%. 16 manufacturers reported payments, led by Medtronic at 46.1% of the total. Reporting peaked in 2023 at $2,833 and has fallen 98.9% since, to $31 in 2025. Among family clinicians in WI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$5,150in general payments, 2019–2025

Across 111 payments — averaging $46.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$2K
  • Nevro Corp.$654
  • Nalu Medical, Inc.$623
  • Tersera Therapeutics LLC$298
  • Collegium Pharmaceutical, Inc.$278
  • Ferring Pharmaceuticals Inc.$195
  • plus $727 from 10 others

What the payments were for

  • Travel & lodging$1,87136%
  • Food & beverage$3,21662%
  • Education$631%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,150 in reported general payments places this provider in the 95th percentile of 1,273 family providers in Wisconsin.

See all family providers in Wisconsin

Medicare billing

Part B allowed, 2024
$22,925
Medicare patients
158
Services billed
283

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Xtampza ErOxycodone Myristate26$14,478
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen289$7,543
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen238$6,644
Buprenorphine20$5,324
Morphine Sulfate ErMorphine Sulfate114$3,071
Gabapentin199$2,675
Lidocaine22$2,084
Pregabalin68$1,923
Tizanidine Hcl130$1,355
Naloxone Hcl20$1,236
Fentanyl18$1,144
Tramadol Hcl101$946
Duloxetine Hcl40$863
Morphine Sulfate39$832
Baclofen49$572

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er$278$14,47826 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,273 family providers in Wisconsin.

Other family in Milwaukee

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →